ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:DUL - US02043Q1076 - Common Stock
DUL.DE Key Statistics, Chart & Performance
The current stock price of DUL.DE is 333.5 EUR.
DUL.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 71.06 | 46.37B | ||
| 1AE.DE | ARGENX SE | 70.98 | 46.32B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.49B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.42B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.39B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.79B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.79B | ||
| 1CVAC.MI | CUREVAC NV | 5.04 | 987.60M | ||
| 5CV.DE | CUREVAC NV | 7.43 | 970.48M | ||
| NANO.PA | NANOBIOTIX | N/A | 938.27M | ||
| IVA.PA | INVENTIVA SA | N/A | 718.23M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M |
Related stock screener links
About DUL.DE
Company Profile
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Company Info
ALNYLAM PHARMACEUTICALS INC
675 W Kendall St
Cambridge MASSACHUSETTS US
Employees: 2230
Phone: 16175518200
ALNYLAM PHARMACEUTICALS INC / DUL.DE FAQ
What does DUL do?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Can you provide the latest stock price for ALNYLAM PHARMACEUTICALS INC?
The current stock price of DUL.DE is 333.5 EUR. The price decreased by -8.15% in the last trading session.
Does DUL stock pay dividends?
DUL.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of DUL stock?
DUL.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How many employees does ALNYLAM PHARMACEUTICALS INC have?
ALNYLAM PHARMACEUTICALS INC (DUL.DE) currently has 2230 employees.
What is the market capitalization of DUL stock?
ALNYLAM PHARMACEUTICALS INC (DUL.DE) has a market capitalization of 44.06B EUR. This makes DUL.DE a Large Cap stock.
DUL.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DUL.DE.
DUL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to DUL.DE. Both the profitability and the financial health of DUL.DE get a neutral evaluation. Nothing too spectacular is happening here.
DUL.DE Financial Highlights
Over the last trailing twelve months DUL.DE reported a non-GAAP Earnings per Share(EPS) of 0.43. The EPS increased by 119.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.36% | ||
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| Debt/Equity | 4.45 |
DUL.DE Forecast & Estimates
37 analysts have analysed DUL.DE and the average price target is 393.52 EUR. This implies a price increase of 18% is expected in the next year compared to the current price of 333.5.
For the next year, analysts expect an EPS growth of 186.28% and a revenue growth 67.16% for DUL.DE